Eleven Biotherapeutics

Press Releases
 
Press Releases
Date Title and Summary View
January 2, 2014
PDF
Add to Briefcase
December 23, 2013 Eleven Biotherapeutics Establishes Scientific Advisory Board to Guide Ophthalmic Pipeline and Technology Development ...
November 12, 2013 Eleven Biotherapeutics to Present Clinical Data on Lead Drug Candidate, EBI-005 ...
September 24, 2013 Eleven Biotherapeutics to Present at the Targeting Ocular Disorders Conference ...
September 20, 2013 Eleven Biotherapeutics Presents Positive Clinical Data on EBI-005, a Targeted Protein Therapeutic for Highly Selective Topical Blockade of IL-1 in Patients with Dry Eye Disease ...
September 5, 2013 Eleven Biotherapeutics to Present at the Stifel Nicolaus 2013 Healthcare Conference ...
June 28, 2013 Eleven Biotherapeutics Announces Positive Topline Data on EBI-005, a Novel Topical IL-1 Inhibitor Protein Therapeutic, in Patients with Dry Eye Disease ...
June 28, 2013 Eleven Biotherapeutics Appoints Industry Veteran Karen L. Tubridy as Chief Development Officer ...
May 28, 2013 Eleven Biotherapeutics Announces Collaboration with ThromboGenics to Develop a Novel Protein Therapeutic for Ophthalmic Disease ...
May 8, 2013 Eleven Biotherapeutics Presents Data on EBI-005, a Novel IL-1 Inhibitor Protein Therapeutic for Topical Treatment of Dry Eye Disease ...
FirstPrevious ...
9
NextLast
Add to Briefcase = add release to Briefcase
NASDAQ: EBIO
Price:
1.58
Change:
- 0.04
Day High:
1.67
Day Low:
1.54
Volume:
243,228
12:08 PM ET on September 20, 2017
Delayed at least 20 minutes.